JP2006514004A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514004A5 JP2006514004A5 JP2004550229A JP2004550229A JP2006514004A5 JP 2006514004 A5 JP2006514004 A5 JP 2006514004A5 JP 2004550229 A JP2004550229 A JP 2004550229A JP 2004550229 A JP2004550229 A JP 2004550229A JP 2006514004 A5 JP2006514004 A5 JP 2006514004A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- cells
- cell
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42309002P | 2002-10-30 | 2002-10-30 | |
| US60/423,090 | 2002-10-30 | ||
| PCT/US2003/034429 WO2004042009A2 (en) | 2002-10-30 | 2003-10-29 | Inhibition of il-17 production |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010210980A Division JP5705483B2 (ja) | 2002-10-30 | 2010-09-21 | Il−17産生の阻害 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006514004A JP2006514004A (ja) | 2006-04-27 |
| JP2006514004A5 true JP2006514004A5 (cg-RX-API-DMAC7.html) | 2006-10-19 |
| JP5477998B2 JP5477998B2 (ja) | 2014-04-23 |
Family
ID=32312602
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004550229A Expired - Lifetime JP5477998B2 (ja) | 2002-10-30 | 2003-10-29 | Il−17産生の阻害 |
| JP2010210980A Expired - Lifetime JP5705483B2 (ja) | 2002-10-30 | 2010-09-21 | Il−17産生の阻害 |
| JP2013123690A Expired - Lifetime JP5870067B2 (ja) | 2002-10-30 | 2013-06-12 | Il−17産生の阻害 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010210980A Expired - Lifetime JP5705483B2 (ja) | 2002-10-30 | 2010-09-21 | Il−17産生の阻害 |
| JP2013123690A Expired - Lifetime JP5870067B2 (ja) | 2002-10-30 | 2013-06-12 | Il−17産生の阻害 |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US7510709B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1576011B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5477998B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR101053412B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN1711282B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE439166T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003287257C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2501786C (cg-RX-API-DMAC7.html) |
| DE (1) | DE60328823D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1576011T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2329673T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL167845A (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05004512A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ539271A (cg-RX-API-DMAC7.html) |
| PT (1) | PT1576011E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004042009A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200503013B (cg-RX-API-DMAC7.html) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6706264B1 (en) * | 1994-03-14 | 2004-03-16 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y |
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
| ES2292242T5 (es) | 1998-05-15 | 2011-05-04 | Genentech, Inc. | Utilizaciones terapéuticas de polipéptidos homólogos de il-17. |
| US20040043397A1 (en) * | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US20030203451A1 (en) * | 2000-08-24 | 2003-10-30 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US7718397B2 (en) * | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
| US7422743B2 (en) * | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| US20040219150A1 (en) * | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
| EP1623011B1 (en) | 2003-05-09 | 2013-01-02 | Janssen Biotech, Inc. | Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses |
| DK1641822T3 (da) | 2003-07-08 | 2013-07-22 | Genentech Inc | Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf. |
| EP1983000B1 (en) * | 2003-11-21 | 2015-09-02 | UCB Biopharma SPRL | Method for the treatment of multiple sclerosis by inhibiting IL-17 activity |
| US20050226878A1 (en) * | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
| JP2007513165A (ja) * | 2003-12-02 | 2007-05-24 | スリーエム イノベイティブ プロパティズ カンパニー | Irm化合物を含む併用薬および治療方法 |
| CN1942201B (zh) * | 2004-02-17 | 2012-06-20 | 先灵公司 | 调节il-23活性的方法;相关试剂 |
| US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
| AU2005241020B2 (en) * | 2004-05-03 | 2008-07-10 | Merck Sharp & Dohme Corp. | Use of IL-17 expression to predict skin inflammation; methods of treatment |
| AR051444A1 (es) | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
| EP1853707A2 (en) * | 2004-12-20 | 2007-11-14 | Schering Corporation | Uses of il-23 antagonists in the treatment of diabetes mellitus |
| CA2596706A1 (en) * | 2005-01-04 | 2006-07-13 | University Of Rochester | Blockade of elr+cxc chemokines as a treatment for inflammatory and autoimmune disease |
| CN103145837A (zh) * | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
| CA2613818C (en) | 2005-06-30 | 2013-08-27 | Centocor, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
| ME02705B (me) | 2005-08-31 | 2017-10-20 | Merck Sharp & Dohme | Inženjerisana anti-il-23 antitela |
| DE602006009834D1 (de) * | 2005-09-01 | 2009-11-26 | Schering Corp | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung |
| JP2009518314A (ja) * | 2005-12-02 | 2009-05-07 | ジェネンテック・インコーポレーテッド | Il−22に結合する抗体およびil−22rに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法 |
| SI3219328T1 (sl) | 2005-12-29 | 2020-10-30 | Janssen Biotech, Inc. | Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| HUE052220T2 (hu) | 2006-09-08 | 2021-04-28 | Abbvie Bahamas Ltd | Interleukin-13 kötõfehérjék |
| US8414897B1 (en) * | 2006-10-02 | 2013-04-09 | The Uab Research Foundation | Pathway for Th-17 cell development and methods utilizing same |
| TWI426918B (zh) * | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
| HUE042172T2 (hu) | 2007-02-23 | 2019-06-28 | Merck Sharp & Dohme | Genetikailag elõállított anti-il-23P19 antitestek |
| CA2679381A1 (en) * | 2007-02-28 | 2008-09-04 | Schering Corporation | Engineered anti-il-23r antibodies |
| JPWO2009054454A1 (ja) | 2007-10-24 | 2011-03-03 | 国立大学法人 東京医科歯科大学 | カテプシン阻害剤を有効成分として含有するToll様受容体のシグナル伝達の調整剤 |
| CA2717987C (en) * | 2008-04-29 | 2018-11-13 | Micromet Ag | Inhibitors of gm-csf and il-17 for therapy |
| BRPI0908312A2 (pt) | 2008-05-05 | 2015-08-18 | Novimmune Sa | '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular'' |
| JP2012508563A (ja) * | 2008-11-12 | 2012-04-12 | シェーリング コーポレイション | 抗IGF1R発現の増強のためのβGl−IGGイントロン |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| EP2427203B1 (en) | 2009-05-05 | 2018-10-17 | Novimmune S.A. | Anti-il-17f antibodies and use thereof |
| JP2011032170A (ja) * | 2009-07-29 | 2011-02-17 | Morinaga Milk Ind Co Ltd | ヒト細胞il−17産生抑制剤 |
| EP2480251B1 (en) | 2009-09-21 | 2025-12-03 | Peptinov | Carrier conjugates of il-23-peptides and their induced antibodies |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| US20120252896A1 (en) * | 2009-11-20 | 2012-10-04 | Ernst Joel D | Methods and compositions for modulation of t-cells via the kynurenine pathway |
| GB201013975D0 (en) | 2010-08-20 | 2010-10-06 | Imp Innovations Ltd | Method of treating desease |
| CN102010903A (zh) * | 2010-08-26 | 2011-04-13 | 中国医学科学院肿瘤研究所 | Il-23在肝癌早期病变诊断中的应用 |
| KR102049223B1 (ko) | 2010-11-04 | 2019-11-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-il-23 항체 |
| EP2809660B1 (en) | 2012-02-02 | 2016-01-20 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| CN109206516A (zh) | 2012-05-03 | 2019-01-15 | 勃林格殷格翰国际有限公司 | 抗IL-23p19抗体 |
| CA2911946A1 (en) | 2013-05-10 | 2014-11-13 | Numab Ag | Bispecific constructs and their use in the treatment of various diseases |
| RU2714919C2 (ru) | 2013-08-30 | 2020-02-21 | Такеда Гмбх | Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков |
| EP3172339A1 (en) | 2014-07-24 | 2017-05-31 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| CA2959629C (en) | 2014-09-03 | 2023-10-31 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
| AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| KR20170120616A (ko) | 2015-02-04 | 2017-10-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 염증성 질환의 치료 방법 |
| CA3023451A1 (en) * | 2016-05-06 | 2017-11-09 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna |
| MA55149A (fr) | 2018-11-20 | 2021-09-29 | Janssen Biotech Inc | Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23 |
| EP3972690A4 (en) | 2019-05-23 | 2023-07-05 | Janssen Biotech, Inc. | METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA |
| TW202535466A (zh) | 2019-09-09 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| KR20230017211A (ko) * | 2020-04-30 | 2023-02-03 | 얀센 파마슈티카 엔.브이. | Il-17 경로의 조절인자를 식별하는 방법 |
| CA3183927A1 (en) | 2020-05-21 | 2021-11-25 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| CN112300285B (zh) * | 2020-11-06 | 2022-08-02 | 江苏荃信生物医药股份有限公司 | 一种定量检测血清中抗人白介素17单克隆抗体含量的酶联免疫分析方法 |
| CN116183472B (zh) * | 2023-04-25 | 2023-08-18 | 上海益诺思生物技术股份有限公司 | Cba法检测非人类灵长类动物细胞因子的验证方法 |
| WO2026058045A1 (en) | 2024-09-12 | 2026-03-19 | Takeda Pharmaceutical Company Limited | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060284A (en) * | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
| ZA986596B (en) | 1997-07-25 | 1999-02-08 | Schering Corp | Mammalian cytokine related reagents |
| ATE474849T1 (de) * | 1998-04-14 | 2010-08-15 | Chugai Pharmaceutical Co Ltd | Neues cytokinartiges protein |
| US6448081B1 (en) * | 2001-05-07 | 2002-09-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of interleukin 12 p40 subunit expression |
| KR20010089764A (ko) * | 1999-01-11 | 2001-10-08 | 둘락 노먼 씨. | 인터류킨-17과 관련된 포유류의 사이토카인, 이를코딩하는 폴리뉴클레오티드 및 이의 용도 |
| US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| BR0009323A (pt) | 1999-03-25 | 2002-01-08 | Knoll Gmbh | Anticorpos humanos que ligam a il-12 humana e métodos para a produção |
| US20030082734A1 (en) * | 1999-06-01 | 2003-05-01 | Dowling Lynette M. | Mammalian receptor proteins; related reagents and methods |
| EP1212343A4 (en) | 1999-09-03 | 2004-11-03 | Human Genome Sciences Inc | 52 human secreted proteins |
| DE60038304T3 (de) | 1999-09-09 | 2017-04-06 | Merck Sharp & Dohme Corp. | Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen |
| EP1221482B1 (en) * | 1999-09-27 | 2005-12-28 | Chugai Seiyaku Kabushiki Kaisha | Hemopoietin receptor protein, nr12 |
| US7422743B2 (en) * | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| US6756481B2 (en) * | 2000-05-10 | 2004-06-29 | Schering Corporation | IL-23 receptor binding compositions |
| US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| JP3899861B2 (ja) * | 2001-07-13 | 2007-03-28 | 株式会社日立製作所 | 光ディスク、情報再生方法及び記録方法 |
| ATE440864T1 (de) * | 2003-03-10 | 2009-09-15 | Schering Corp | Verwendung von il-23-antagonisten; verwandte reagenzien |
| CA2545340A1 (en) * | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Fused heterocyclic compounds |
| EP1687004A4 (en) | 2003-11-10 | 2009-04-08 | Synta Pharmaceuticals Corp | PYRIDINE COMPOUNDS |
| JP4851337B2 (ja) | 2003-11-10 | 2012-01-11 | シンタ ファーマシューティカルズ コーポレーション | ヘテロアリールヒドラゾン化合物 |
| CN1942201B (zh) * | 2004-02-17 | 2012-06-20 | 先灵公司 | 调节il-23活性的方法;相关试剂 |
| US20050287593A1 (en) * | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
| AU2005241020B2 (en) | 2004-05-03 | 2008-07-10 | Merck Sharp & Dohme Corp. | Use of IL-17 expression to predict skin inflammation; methods of treatment |
| AR051444A1 (es) * | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
| KR101004362B1 (ko) | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | 자가 면역 질환 예방 및 치료용 TNF-α와 TWEAK 이중 길항제 |
-
2003
- 2003-10-29 NZ NZ539271A patent/NZ539271A/en not_active IP Right Cessation
- 2003-10-29 JP JP2004550229A patent/JP5477998B2/ja not_active Expired - Lifetime
- 2003-10-29 PT PT03781490T patent/PT1576011E/pt unknown
- 2003-10-29 AT AT03781490T patent/ATE439166T1/de active
- 2003-10-29 CN CN2003801027073A patent/CN1711282B/zh not_active Expired - Lifetime
- 2003-10-29 ES ES03781490T patent/ES2329673T3/es not_active Expired - Lifetime
- 2003-10-29 MX MXPA05004512A patent/MXPA05004512A/es active IP Right Grant
- 2003-10-29 CN CN2010101439342A patent/CN101824088B/zh not_active Expired - Lifetime
- 2003-10-29 KR KR1020117003939A patent/KR101053412B1/ko not_active Expired - Lifetime
- 2003-10-29 EP EP03781490A patent/EP1576011B1/en not_active Revoked
- 2003-10-29 DK DK03781490T patent/DK1576011T3/da active
- 2003-10-29 WO PCT/US2003/034429 patent/WO2004042009A2/en not_active Ceased
- 2003-10-29 US US10/697,599 patent/US7510709B2/en not_active Expired - Lifetime
- 2003-10-29 KR KR1020057007502A patent/KR101076931B1/ko not_active Expired - Lifetime
- 2003-10-29 AU AU2003287257A patent/AU2003287257C1/en not_active Expired
- 2003-10-29 EP EP20090007964 patent/EP2108660A1/en not_active Ceased
- 2003-10-29 CA CA2501786A patent/CA2501786C/en not_active Expired - Lifetime
- 2003-10-29 DE DE60328823T patent/DE60328823D1/de not_active Expired - Lifetime
-
2005
- 2005-04-04 IL IL167845A patent/IL167845A/en unknown
- 2005-04-14 ZA ZA200503013A patent/ZA200503013B/en unknown
-
2009
- 2009-01-07 US US12/350,089 patent/US20100266582A1/en not_active Abandoned
- 2009-01-07 US US12/350,125 patent/US8287869B2/en not_active Expired - Lifetime
-
2010
- 2010-09-21 JP JP2010210980A patent/JP5705483B2/ja not_active Expired - Lifetime
-
2012
- 2012-10-11 US US13/649,810 patent/US20130309194A1/en not_active Abandoned
-
2013
- 2013-06-12 JP JP2013123690A patent/JP5870067B2/ja not_active Expired - Lifetime
-
2016
- 2016-03-10 US US15/066,568 patent/US20160326229A1/en not_active Abandoned
-
2018
- 2018-04-19 US US15/957,879 patent/US20190092829A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5477998B2 (ja) | Il−17産生の阻害 | |
| US8187596B1 (en) | Method of treating asthma or allergy by administering an IL-33 receptor antibody | |
| US20090142806A1 (en) | Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor | |
| JP2009543579A (ja) | 抗炎症反応のための標的としてのWSX−1/p28 | |
| US20120263733A1 (en) | Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation | |
| EP2171044A1 (en) | Th-17 cells | |
| HK1135415A (en) | Inhibition of il-17 production |